Peter Tan

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein et al. · Journal of Clinical Oncology · 2020 · 174 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients

Chindu Govindaraj, Peter Tan, Patricia Walker et al. · Clinical Cancer Research · 2013 · 81 citations · Full text

Medicine, Immunology, Oncology +17

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Daniel A. Pollyea, Jacqueline S. Garcia et al. · Blood · 2019 · 72 citations

Medicine, Pharmacotherapy, Chemotherapy +7

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations

Elias Jabbour, Emma Searle, Maher Abdul‐Hay et al. · Blood · 2023 · 49 citations

Medicine, Oncology, Pharmacotherapy +11

Lenalidomide‐based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients

Chindu Govindaraj, Mutsa Madondo, Ying Kong et al. · American Journal of Hematology · 2014 · 46 citations

Life Sciences, Immunology, Pharmacology +17